Cargando…
A Peptide Meets a Radionuclide to Combat a Rare Tumor
Background: Neuroendocrine carcinomas (NECs) are rare malignancies with limited treatment options beyond surgery. Peptide receptor radionuclide therapy (PRRT) is a process by which a somatostatin analog (octreotate) is combined with a chelator (DOTA) and a radionuclide (lutetium-177 [(177)Lu-dotatat...
Autores principales: | Thomas, Katharine E., Boudreaux, J. Philip, Thiagarajan, Ramcharan, Marsala, Andrew, Voros, Brianne A., Ramirez, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Division of Ochsner Clinic Foundation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442225/ https://www.ncbi.nlm.nih.gov/pubmed/34566515 http://dx.doi.org/10.31486/toj.20.0098 |
Ejemplares similares
-
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
por: Thomas, Katharine, et al.
Publicado: (2020) -
A Neuroendocrine Tumor Specialty Center in New Orleans’ (NOLANETS) Response to Patient Care During the COVID‐19 Pandemic
por: Ramirez, Robert A., et al.
Publicado: (2020) -
Castleman's Disease: A Rare Mass in the Pararenal Retroperitoneum that Mimics Other Tumors
por: Xie, Yi, et al.
Publicado: (2017) -
Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and bla(NDM-5): Preparation for a Postantibiotic Era
por: Bulman, Zackery P., et al.
Publicado: (2017) -
Fibronectin Glomerulopathy: A Rare Autosomal Dominant Glomerular Disease
por: Wu, Jing, et al.
Publicado: (2017)